Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Retraction: Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer
Norah F. Alqahtania,
Mohammad Y. Alfaifibc,
Ali Shati Abc,
Serag Eldin I. Elbehairibcd,
Abdulrahman M. Salehef,
Ebtesam S. Kotbg,
Waleed M. Serag*g,
Reda F. M. Elshaarawygh,
Heba W. Alhamdii and
Yasser A. Hassanjk
aDepartment of Chemistry, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia
bKing Khalid University, Faculty of Science, Biology Department, Abha 9004, Saudi Arabia
cTissue Culture and Cancer Biology Research Laboratory, King Khalid University, Abha, 9004, Saudi Arabia
dCell Culture Lab, Egyptian Organization for Biological Products and Vaccines (VACSERA Holding Company), 51 Wezaret El-Zeraa St., Agouza, Giza, Egypt
eDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
fAweash El-Hagar Family Medicine Center, Epidemiological Surveillance Unit, MOHP, Mansoura 35711, Egypt
gDepartment of Chemistry, Faculty of Science, Suez University, 43533 Suez, Egypt. E-mail: waleed.ibrahim@suezuniv.edu.eg
hInstitut für Anorganische Chemie und Strukturchemie, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
iCollege of Sciences, Biology Department, King Khalid University, Abha 61413, Saudi Arabia
jDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt
kDepartment of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Al-Kitab University, Kirkuk, Iraq
First published on 28th May 2026
Abstract
Retraction of ‘Molecular docking and in vivo/in vitro studies of a novel thiadiazole Schiff base as a hepatoprotective drug against angiogenesis induced by breast cancer’ by Norah F. Alqahtani et al., RSC Adv., 2024, 14, 39027–39039, https://doi.org/10.1039/D4RA06398H.
The Royal Society of Chemistry, hereby wholly retracts this RSC Advances article due to concerns with the reliability of the data.
Concerns were raised regarding the Fig. 4 micrographs, which were previously published by the same authors in ref. 1, and the Fig. 10 flow cytometry plots, which were previously published in ref. 2 by different authors. The corresponding author has cooperated fully with our investigation and said that the duplication in Fig. 4 was due to the authors working on the same projects in parallel. They say that the wrong set of processed images were mistakenly inserted into the RSC Advances manuscript and have provided replacement images. The authors have acknowledged the issues with the Fig. 10 Flow Cytometry plots, and claim that these were outsourced to a third-party laboratory but have not been able to provide any evidence of this.
We attempted to inform all authors about the retraction of the article, but have we have not been able to reach Serag Eldin I. Elbehairi, Ebtesam S. Kotb, Abdulrahman M. Saleh, Ali Shati A, Mohammad Y. Alfaifi and Heba W. Alhamdi.
Waleed M. Serag has not indicated whether they agree with the decision to retract. The other authors have not responded.
Given the significance of these concerns, the Editor has lost confidence that the findings presented in this paper are reliable.
Signed: Laura Fisher, Executive Editor, RSC Advances
Date: 20th May 2026
References
- E. S. Kotb, H. W. Alhamdi, M. Y. Alfaifi, O. Darweesh, A. A. Shati, S. E. I. Elbehairi, W. M. Serag, Y. A. Hassan and R. F. M. Elshaarawy, Int. J. Biol. Macromol., 2024, 133616 CrossRef CAS PubMed.
- I. Zaki, A. M. Y. Moustafa, B. Y. Beshay, R. E. Masoud, M. A. I. Elbastawesy, M. A. S. Abourehab and M. Y. Zakaria, J. Enzym. Inhib. Med. Chem., 2022, 37, 2679–2701 CrossRef CAS PubMed.
| This journal is © The Royal Society of Chemistry 2026 |